(vianews) - vistin pharma (vistn.ol) is among this list of stock assets with the highest dividend rate and return on equity on the healthcare sector.
| financial asset | price | forward dividend yield | return on equity |
|---|---|---|---|
| vistin pharma (vistn.ol) | kr22.60 | 7.95% | 19.84% |
| ucb (ucb.br) | €130.60 | 1.06% | 3.8% |
| ipsen (ipn.pa) | €110.30 | 1% | 17.3% |
several euronext companies pay out dividends to its shareholders. the dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. vistin pharma (vistn.ol)
7.95% forward dividend yield and 19.84% return on equity
vistin pharma asa, through its subsidiary, vistin pharma as, produces and sells active pharmaceutical ingredients (apis) worldwide. it offers metformin hcl apis and direct compressive granulates for the pharmaceutical industry. vistin pharma asa was founded in 1969 and is headquartered in oslo, norway.
earnings per share
as for profitability, vistin pharma has a trailing twelve months eps of kr1.27.
pe ratio
vistin pharma has a trailing twelve months price to earnings ratio of 17.8. meaning, the purchaser of the share is investing kr17.8 for every norwegian krone of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 19.84%.
sales growth
vistin pharma's sales growth is 10.6% for the ongoing quarter and 6.6% for the next.
revenue growth
year-on-year quarterly revenue growth grew by 2.9%, now sitting on 441.27m for the twelve trailing months.
stock price classification
according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, vistin pharma's stock is considered to be oversold (<=20).
more news about vistin pharma.
2. ucb (ucb.br)
1.06% forward dividend yield and 3.8% return on equity
ucb sa, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. the company's primary products include cimzia for inflammatory tnf mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; vimpat, keppra, and briviact for epilepsy; neupro for parkinson's disease and restless legs syndrome; nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and zyrtec and xyzal for allergies. it also offers evenity for the treatment of osteoporosis in postmenopausal women; bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and fintepla to treat dravet syndrome. in addition, the company is involved in developing rozanolixizumab and zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat cdkl5 deficiency disorder; doxecitine for tk2 deficiency disorder; staccato alprazolam for stereotypical prolonged seizures; bepranemab to treat alzheimer's disease; minzasolmin and ucb0222 for parkinson's disease; and ucb1381 and ucb9741 for atropic dermatitis. further, it engages in contract manufacturing activities. ucb sa has collaboration agreements with amgen, biogen, roche/genentech, novartis, and otsuka. the company was incorporated in 1925 and is headquartered in brussels, belgium.
earnings per share
as for profitability, ucb has a trailing twelve months eps of €1.76.
pe ratio
ucb has a trailing twelve months price to earnings ratio of 74.2. meaning, the purchaser of the share is investing €74.2 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 3.8%.
more news about ucb.
3. ipsen (ipn.pa)
1% forward dividend yield and 17.3% return on equity
ipsen s.a. operates as a biopharmaceutical company worldwide. the company provides drugs in the areas of oncology, neuroscience, and rare diseases. its product pipeline comprises cabometyx + atezolizumab, which is in phase iii clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and taverik, which is in phase iii for the treatment of second line follicular lymphoma; bylvay, which is in phase iii for the treatment of biliary atresia; dysport, which is in phase iii clinical trial for the treatment of chronic and episodic migraine; fidrisertib, which is in phase ii clinical trial for the treatment of fibrodysplasia ossificans progressiva; elafibranor, which is in phase ii for the treatment of primary sclerosing cholangitis, as well as ipn60250; ipn10200, which is in phase ii for the treatment of longer-acting neurotoxin aesthetics and therapeutics; ipn60210, which is in phase i clinical trial for the treatment of relapsed/refractory multiple myeloma; and ipn60260 for the treatment of viral cholestatic disease and is in phase i clinical trial. the company also offers somatuline, decapeptyl, cabometyx, onivyde, tazverik, and other oncology products; dysport and other neurosciences products; and bylvay, nutropinaq, increlex, and sohonos for rare diseases. the company was founded in 1929 and is based in boulogne-billancourt, france.
earnings per share
as for profitability, ipsen has a trailing twelve months eps of €7.4.
pe ratio
ipsen has a trailing twelve months price to earnings ratio of 14.91. meaning, the purchaser of the share is investing €14.91 for every euro of annual earnings.
return on equity
the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.3%.
more news about ipsen.